Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 588
- Registration Number
- NCT02827578
- Locations
- 🇰🇷
Samsung medical center, Seoul, Korea, Republic of
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
- Conditions
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Astellas Pharma Taiwan, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02715024
- Locations
- 🇨🇳
Site, Taipei, Taiwan
Reproducibility Study of OABSS and Its Response to Treatment
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT02667470
- Locations
- 🇹🇭
Site: 1, Bangkok, Thailand
EC905 Pharmacokinetic Profile Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 46
- Registration Number
- NCT02634489
- Locations
- 🇳🇱
Site NL1, Zuidlaren, Drente, Netherlands
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2019-03-05
- Target Recruit Count
- 28
- Registration Number
- NCT02549196
- Locations
- 🇺🇸
PMG Research, Winston-Salem, North Carolina, United States
🇺🇸Quantum Laboratories, Deerfield Beach, Florida, United States
🇺🇸Miami Jewish Health Systems, Miami, Florida, United States
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 113
- Registration Number
- NCT02540707
- Locations
- 🇨🇳
Outpatient clinics, Department of Obs/Gyn, National Taiwan University Hospital, Taipei, Taiwan
Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2015-05-25
- Target Recruit Count
- 180
- Registration Number
- NCT02452879
- Locations
- 🇨🇳
Guang'an Men Hospotal Affiliated to China Academy of Chinese Medical Sciences, Beijing, Beijing, China
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
- Conditions
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02180997
- Locations
- 🇰🇷
Seoul National University Hospital(SNUH), Seoul, Jongno-Gu, Korea, Republic of
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 20
- Registration Number
- NCT02169713
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 26
- Registration Number
- NCT02127034
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.